| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2481267 | European Journal of Pharmaceutical Sciences | 2011 | 6 Pages |
Abstract
Cimetidine, H2 receptor antagonists, is commonly prescribed for gastric and duodenal ulcer disease. Additionally, cimetidine has been shown to have anticancer effects. This review describes the mechanism of antitumor action of cimetidine including its ability to interfere with tumor cell adhesion, angiogenesis and proliferation; its effect on the immune system; as well as inhibition of postoperative immunosuppression. Its anticancer effect is also compared to that of the other H2 receptor antagonists as well as outcomes of cimetidine in clinical studies in cancer patients.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Martina Kubecova, Katarina Kolostova, Daniela Pinterova, Grzegorz Kacprzak, Vladimir Bobek,